Comparative Pharmacology
Head-to-head clinical analysis: AMCINONIDE versus DERMA SMOOTHE FS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCINONIDE versus DERMA SMOOTHE FS.
AMCINONIDE vs DERMA-SMOOTHE/FS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
None Documented
None Documented
Clinical Note
moderateAmcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin."
Clinical Note
moderateAmcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin."
Clinical Note
moderateAmcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin."
Clinical Note
moderateAmcinonide + Trovafloxacin
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin."